Renalys Pharma is a technology company.
Renalys Pharma has raised $39.0M across 1 funding round.
Renalys Pharma has raised $39.0M in total across 1 funding round.
Renalys Pharma is a clinical-stage biopharmaceutical company based in Japan, focused on developing and commercializing innovative therapies for renal diseases, particularly targeting IgA nephropathy, focal segmental glomerulosclerosis (FSGS), and Alport syndrome in Japan and select Asian countries.[1][2][3] The company centers on sparsentan (FILSPARI), an investigational dual endothelin and angiotensin receptor antagonist licensed from Travere Therapeutics, addressing unmet needs in kidney disease management for Asian patients who face "drug lag" delays in accessing global therapies.[1][3][5] It serves patients with rare kidney conditions, solving the problem of limited treatment options through late-stage clinical development and commercialization, backed initially by ¥6.0 billion in Series A financing to complete Phase III trials.[5] As of late 2025, Renalys has completed primary endpoint data collection in its Japan Phase III trial for sparsentan in IgA nephropathy, with topline results expected in Q4 2025, and has advanced registrational plans for FSGS and Alport syndrome.[3][4]
Renalys Pharma was founded in 2023 (launched publicly on January 25, 2024) by Catalys Pacific, a transpacific life sciences investment firm, and SR One, a transatlantic life sciences investor, to bridge Asia's "drug lag" in renal treatments.[1][2][5] BT Slingsby, MD, PhD, MPH, serves as CEO, Representative Director, Chairman, and Co-Founder, bringing expertise from Catalys Pacific where he is Founder and Managing Director; the team includes former Kyowa Kirin executives who led launches of landmark renal therapies.[1][2] The idea emerged from investor partnerships recognizing the need for rapid access to proven global therapies like sparsentan in Japan and Asia, with Renalys securing exclusive licensing rights from Travere Therapeutics via upfront and milestone payments.[1][3][6] Early traction included a ¥6.0 billion Series A in 2024 to fund Phase III completion, IND submission to Japan's PMDA, and initiation of registrational studies.[5]
Renalys rides the trend of global biopharma collaboration to close regional treatment gaps, particularly Asia's "drug lag" where patients wait years for therapies like sparsentan already approved in the US (full FDA approval 2024) and EU.[1][3][4] Timing aligns with rising IgA nephropathy prevalence in Japan/Asia and regulatory progress (e.g., PMDA agreements, NHS endorsement in UK 2025), fueled by market forces like aging populations and demand for dual-acting renal therapies.[3][5][6] By licensing and advancing US/EU innovations locally, Renalys influences the ecosystem through investor models like Catalys Pacific's (e.g., Mineralys, Pathalys, Aculys), proving scalable pathways for borderless science and accelerating patient access via Chugai's infrastructure.[2][4]
Renalys Pharma's acquisition by Chugai positions it for accelerated commercialization, with Q4 2025 topline Phase III results for sparsentan in IgA nephropathy likely paving the way for Japan approval and launches in South Korea/Taiwan.[3][4][6] Trends like expanded renal indications (FSGS, Alport) and Chugai's kidney portfolio synergy will shape growth, potentially evolving Renalys into a regional leader in rare kidney disease therapies amid global biopharma consolidation.[3][4][7] This scales its promise to eliminate drug lag, transforming access for Asian patients and exemplifying investor-driven innovation in life sciences.[1]
Renalys Pharma has raised $39.0M in total across 1 funding round.
Renalys Pharma's investors include ARCH Venture Partners, Atlas Venture, Krishna Yeshwant, Pfizer Venture Investments, RA Capital, SR One, Bill Gates.
Renalys Pharma has raised $39.0M across 1 funding round. Most recently, it raised $39.0M Series A in July 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2024 | $39.0M Series A | ARCH Venture Partners, Atlas Venture, Krishna Yeshwant, Pfizer Venture Investments, RA Capital, SR One, Bill Gates |